AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Genuit Group PLC

AGM Information May 21, 2020

4912_dva_2020-05-21_cf45770f-aaac-4376-9129-0a3b0cd5abe6.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 6631N

Polypipe Group PLC

21 May 2020

POLYPIPE GROUP PLC

(the "Company")

Results of Annual General Meeting

21 May 2020

Polypipe Group plc announces that at the Annual General Meeting ("AGM") of the Company held today, all the Resolutions contained in the Notice of AGM were duly passed. 

The total number of proxy votes received in respect of each such resolution 48 hours prior to the

meeting is set out below.

Resolution In favour % Against % Withheld / Abstained
1. To receive the audited accounts of the Company for the year ended 31 December 2019 and the Directors' Report and the Auditor's Report 187,136,052 99.99 0 0 174,503
2. To approve the Directors' Remuneration Report for the year ended 31 December 2019 178,103,276 99.17 1,499,233 0.83 7,708,046
3. To elect Ms Louise Brooke-Smith as a Director of the Company 187,296,417 99.99 4,000 0.01 10,138
4. To elect Ms Lisa Scenna as a Director of the Company 187,296,417 99.99 4,000 0.01 10,138
5. To re-elect Mr Martin Payne as a Director of the Company 184,692,668 98.61 2,610,401 1.39 7,486
6. To re-elect Mr Paul James as a Director of the Company 186,135,627 99.38 1,167,442 0.62 7,486
7. To re-elect Mr Glen Sabin as a Director of the Company 186,154,069 99.39 1,149,000 0.61 7,486
8. To re-elect Mr Ron Marsh as a Director of the Company 181,604,481 98.95 1,922,741 1.05 3,783,333
9. To re-elect Mr Paul Dean as a Director of the Company 185,397,494 98.98 1,902,923 1.02 10,138
10. To re-elect Mr Mark Hammond as a Director of the Company 185,471,853 99.02 1,826,317 0.98 12,385
11. To re-elect Ms Louise Hardy as a Director of the Company 186,396,539 99.52 906,530 0.48 7,486
12. To reappoint Ernst & Young LLP as auditor of the Company 187,303,305 99.99 4,000 0.01 3,250
13. To authorise the Audit Committee to determine auditor's remuneration 187,306,555 99.99 4,000 0.01 0
14. To authorise the Directors to allot shares 181,715,602 97.02 5,588,828 2.98 6,125
15. To approve the Polypipe Group plc International Sharesave Plan 183,659,527 98.06 3,641,903 1.94 9,125
16. To authorise the Directors to allot shares for cash and to disapply pre-emption rights 187,295,664 99.99 8,766 0.01 6,125
17. To authorise the Directors to allot shares for cash and to disapply pre-emption rights in connection with an acquisition or other capital investment 187,266,429 99.98 38,001 0.02 6,125
18. To authorise the Company to make market purchases of its own shares 187,207,780 99.96 69,156 0.04 33,619
19. To authorise the Company to call a general meeting (other than an annual general meeting) on not less than 14 clear days' notice 180,732,926 96.49 6,577,629 3.51 0
20. To approve new Articles of Association 187,303,903 99.99 6,652 0.01 0

The total number of shares on the register at close of business on 21 May 2020, being those eligible to be voted on at the AGM, was 227,963,658.

In accordance with Listing Rule 9.6.2 copies of all resolutions passed as Special Resolutions at the AGM and the updated Articles of Association will be submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

These resolutions will also available on the Polypipe website at http://investors.polypipe.com.

For further enquiries, please contact:

Emma Versluys                                                                                    + 44 (0) 1709 770 000

Company Secretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGEALSFAELEEFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.